Comparison of Amoxicillin and Amoxicillin + Clavulanic Acid in Treating Acute Otitis Media in Children
Comparison of Efficacy of Amoxicillin Plus Clavulanic Acid and Amoxicillin in Children with Acute Otitis Media
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will evaluate the effectiveness of two antibiotic treatments in children diagnosed with acute otitis media, a common ear infection. The two treatments being compared are amoxicillin alone and a combination of amoxicillin and clavulanic acid. Acute otitis media is a significant health concern in children, causing pain, fever, and possible hearing loss.
The study will be conducted as a randomized controlled trial at the Department of Pediatric Medicine, Nishtar Hospital, Multan. A total of 162 children, aged 1 to 5 years, will be enrolled in the study. They will be randomly assigned to one of two treatment groups: one group will receive amoxicillin, and the other group will receive amoxicillin plus clavulanic acid. The children will be monitored throughout their treatment to assess how quickly their symptoms resolve, whether they experience treatment failure or recurrence, and if they develop any side effects.
The study aims to provide clearer evidence on the efficacy of the combination treatment (amoxicillin + clavulanic acid) compared to amoxicillin alone. By analyzing treatment outcomes such as symptom resolution time, side effects, and recurrence, the study will help inform clinical decisions and improve treatment protocols for acute otitis media in pediatric patients. The data will be analyzed using statistical software to determine whether the combination therapy leads to faster recovery and fewer complications. The findings from this study will contribute to better management of upper respiratory infections in children.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Muhammad Arslan
- Phone Number: 03106717292
- Email: drmuhammadarslan1@gmail.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Children aged 1 to 5 years
- Diagnosed with acute otitis media (as per operational definition)
- Both male and female participants
- Parental consent obtained
Exclusion Criteria:
- Children with allergies or contraindications to the trial drugs (amoxicillin or amoxicillin + clavulanic acid)
- Children with asthma or chronic obstructive pulmonary disease (COPD) (as per medical record)
- Children who have received treatment with the trial drugs within the past month
- Children already enrolled in other research programs or who have received trial treatment
- Children with any comorbid conditions that may interfere with the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Amoxicillin Treatment Group
Participants in this arm will receive oral amoxicillin at a dose of 30mg/kg/day.
They will be monitored for the resolution of symptoms, treatment failure, recurrence, and potential side effects over the course of the study.
|
Participants in this group will receive oral amoxicillin at a dosage of 30mg/kg/day.
The treatment will be administered in divided doses for the duration of the study, with the aim of resolving symptoms of acute otitis media in children.
|
|
Active Comparator: Amoxicillin + Clavulanic Acid Treatment Group
Participants in this arm will receive oral amoxicillin combined with clavulanic acid at a dose of 30mg/kg/day.
Like the other group, they will be monitored for symptom resolution, treatment failure, recurrence, and side effects throughout the study.
|
Participants in this group will receive oral amoxicillin at a dosage of 30mg/kg/day.
The treatment will be administered in divided doses for the duration of the study, with the aim of resolving symptoms of acute otitis media in children.
Participants in this group will receive a combination of oral amoxicillin and clavulanic acid at a dosage of 30mg/kg/day.
The medication will be given in divided doses, and participants will be monitored for symptom resolution and any potential side effects.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Symptom Resolution (in Days)
Time Frame: From enrollment to the resolution of symptoms, assessed daily until symptoms are resolved, up to a maximum of 4 weeks.
|
How Measured: The number of days it takes for the symptoms of acute otitis media (fever, ear pain, bulging tympanic membrane) to completely resolve after starting treatment will be recorded. Participants will be assessed daily until the resolution of symptoms. The assessment will be made by the treating physician based on clinical signs observed through otoscopy and patient-reported outcomes (such as pain relief). Criteria for Resolution: Symptoms are considered resolved when the child no longer experiences ear pain, fever, or any other signs of infection. The tympanic membrane will appear normal during otoscopy, with no visible bulging or signs of fluid accumulation. |
From enrollment to the resolution of symptoms, assessed daily until symptoms are resolved, up to a maximum of 4 weeks.
|
|
Number of Participants with Treatment Failure
Time Frame: Assessed at 4 weeks from the start of treatment.
|
Treatment failure is defined as the failure to resolve symptoms within 4 weeks of starting treatment.
If symptoms persist or worsen despite the antibiotic treatment, the physician will classify the case as treatment failure and change the antibiotic regimen.
|
Assessed at 4 weeks from the start of treatment.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Exp130
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.